GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is mentioned in two recent articles covering a historic HIV vaccine trial currently being conducted by the AIDS Research Consortium of Atlanta (ARCA) using a vaccine supplied by GeoVax.
The first article, titled "ARCA Seeks Volunteers For Historic HIV Vaccine Trial," appeared in the June 11 print and online editions of The Georgia Voice, a publication focused on Georgia's LGBT community. In the article, Voice reporter Matt Shafer notes that ARCA is currently seeking volunteers to help test the safety of the GeoVax vaccine, which has shown the potential of reversing HIV viral loads in HIV-positive individuals. He goes on to describe how the vaccine works and details the stringent requirements for participation. The article quotes ARCA's observation that this is the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax.
The second article, titled "Georgia: AIDS Research Consortium of Atlanta Seeks Volunteers for Historic HIV Vaccine Trial," was posted on June 28 on the website The Body: The Complete HIV/AIDS Resource. It is an excerpt of the Voice piece, once again reviewing ARCA's search for trial subjects and stringent participation requirements.
GeoVax CEO Dr. Robert McNally commented, "As I pointed out to The Georgia Voice, we are hopeful that this vaccine will reproduce its effects in humans the way it did in tests conducted on primates. We anticipate that media coverage such as these articles will make it easier to recruit appropriate test subjects, allowing us to initiate the trial in a timely fashion and accelerate our quest to bring a viable vaccine to market."
Nigeria first to rollout new Men5CV vaccine against meningitis